Similar articles

• Proceedings: Sjogren's syndrome: hyperviscosity and intermediate complexes.

  Blaylock WM, Waller M, Normansell DE. Blaylock WM, et al. Arthritis Rheum. 1974 May-Jun;17(3):321. Arthritis Rheum. 1974. PMID: 4825649 No abstract available.
• [The importance of laboratory in the diagnosis in Sjogren's syndrome].

  Britos-Zeron P, Bove A, Perez-de-Lis M, Diaz-Lagares C, Gandia M, Akasbi M, Soto-Cardenas MJ, Perez-Alvarez R, Siso A, Ramos-Casals M. Britos-Zeron P, et al. Rev Fac Cien Med Univ Nac Cordoba. 2009;66(1):14-30. Rev Fac Cien Med Univ Nac Cordoba. 2009. PMID: 21190630 Review. Spanish. No abstract available.
• [Sjögren's disease].

  Bijl M, Panders AK, Vissink A, Nikkels PG, Kallenberg CG. Bijl M, et al. Ned Tijdschr Geneeskd. 1994 May 21;138(21):1049-52. Ned Tijdschr Geneeskd. 1994. PMID: 8202174 Dutch. No abstract available.
• Therapeutic potential for B-cell modulation in Sjögren's syndrome.

  Mariette X. Mariette X. Rheum Dis Clin North Am. 2008 Nov;34(4):1025-33, x. doi: 10.1016/j.rdc.2008.08.014. Rheum Dis Clin North Am. 2008. PMID: 18984420 Review.
• Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjögren's syndrome.

  Girón-González JA, Baturone R, Soto MJ, Márquez M, Macías I, Montes de Oca M, Medina F, Chozas N, García-Pérez S. Girón-González JA, et al. Cell Immunol. 2009;259(1):56-60. doi: 10.1016/j.cellimm.2009.05.013. Epub 2009 Jun 6. Cell Immunol. 2009. PMID: 19540455